ATE452147T1 - Antikörper mit korrigierten cdr - Google Patents

Antikörper mit korrigierten cdr

Info

Publication number
ATE452147T1
ATE452147T1 AT05723312T AT05723312T ATE452147T1 AT E452147 T1 ATE452147 T1 AT E452147T1 AT 05723312 T AT05723312 T AT 05723312T AT 05723312 T AT05723312 T AT 05723312T AT E452147 T1 ATE452147 T1 AT E452147T1
Authority
AT
Austria
Prior art keywords
antibodies
cdr
corrected
selection
present application
Prior art date
Application number
AT05723312T
Other languages
English (en)
Inventor
Mark S Dennis
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34886204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE452147(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE452147T1 publication Critical patent/ATE452147T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05723312T 2004-02-19 2005-02-18 Antikörper mit korrigierten cdr ATE452147T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54584004P 2004-02-19 2004-02-19
PCT/US2005/005270 WO2005080432A2 (en) 2004-02-19 2005-02-18 Cdr-repaired antibodies

Publications (1)

Publication Number Publication Date
ATE452147T1 true ATE452147T1 (de) 2010-01-15

Family

ID=34886204

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05723312T ATE452147T1 (de) 2004-02-19 2005-02-18 Antikörper mit korrigierten cdr

Country Status (9)

Country Link
US (2) US20060122377A1 (de)
EP (3) EP1716181B1 (de)
AT (1) ATE452147T1 (de)
AU (1) AU2005214382B2 (de)
CA (1) CA2555820C (de)
DE (1) DE602005018325D1 (de)
DK (1) DK1716181T3 (de)
ES (1) ES2337473T3 (de)
WO (1) WO2005080432A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004261980A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody CDR polypeptide sequences with restricted diversity
WO2006026759A2 (en) 2004-09-03 2006-03-09 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
JP2008531060A (ja) * 2005-03-04 2008-08-14 バイオジェン・アイデック・エムエイ・インコーポレイテッド 相補性決定残基の合理的改変を介して免疫グロブリン可変領域をヒト化する方法
PE20061444A1 (es) 2005-05-19 2007-01-15 Centocor Inc Anticuerpo anti-mcp-1, composiciones, metodos y usos
BRPI0613382A8 (pt) 2005-06-20 2018-01-02 Genentech Inc anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor
USRE47223E1 (en) 2005-06-20 2019-02-05 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1957531B1 (de) * 2005-11-07 2016-04-13 Genentech, Inc. Bindungspolypeptide mit diversifizierten und konsensus-vh/vl-hypervariablen sequenzen
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2822302A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Methods of impairing osteoclast differentiation
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
US7749772B1 (en) 2006-06-29 2010-07-06 Varian, Inc. Antibody and immunoassays for determining the presence of Δ9-Tetrahydrocannabinol
US20100136030A1 (en) * 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
TW200902554A (en) 2007-05-08 2009-01-16 Genentech Inc Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
CN101939425B (zh) 2007-09-26 2014-05-14 中外制药株式会社 抗il-6受体抗体
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
NZ587632A (en) 2008-03-14 2012-06-29 Biocon Ltd An anti-cd6 monoclonal antibody and a method thereof
WO2010042562A2 (en) 2008-10-06 2010-04-15 Minerva Biotechnologies Corporation Muc1* antibodies
SG175891A1 (en) 2009-05-08 2011-12-29 Genentech Inc Humanized anti-egfl7 antibodies and methods using same
EP2843051B1 (de) 2012-04-23 2018-06-06 GeneFrontier Corporation Anti-human-cd69-antikörper und verwendung davon für medizinische zwecke
ES2723885T3 (es) 2012-07-19 2019-09-03 Daiichi Sankyo Co Ltd Anticuerpos anti-Siglec-15
CA2881966C (en) 2012-08-24 2020-10-06 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
PL220297B1 (pl) * 2012-11-07 2015-10-30 Wrocławskie Ct Badań Eit & Spółka Z Ograniczoną Odpowiedzialności& Epitop i jego zastosowanie
WO2014073292A1 (ja) 2012-11-09 2014-05-15 ジーンフロンティア株式会社 癌治療のための抗adam28抗体
WO2014123186A1 (ja) 2013-02-06 2014-08-14 公立大学法人横浜市立大学 抗セマフォリン３ａ抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療
KR102405247B1 (ko) 2013-07-23 2022-06-07 바이오콘 리미티드 Cd6 결합 파트너의 용도 및 이에 기초한 방법
RS65724B1 (sr) 2013-10-15 2024-08-30 Genefrontier Corp Humano antitelo protiv adamts vrste tipa agrekanaze za terapeutike bolesti povezanih sa agrekanazom
WO2015179435A1 (en) 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
CN116199790A (zh) 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
CN105281984A (zh) * 2015-11-27 2016-01-27 上海斐讯数据通信技术有限公司 一种抓取和过滤报文的虚拟终端和方法
EP3474854A4 (de) 2016-06-27 2020-02-19 The Regents of The University of California Krebsbehandlungskombinationen
PL3529274T3 (pl) 2016-10-21 2024-09-09 Biocon Limited Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
JP7317016B2 (ja) 2017-12-19 2023-07-28 スロゼン オペレーティング， インコーポレイテッド 抗ｌｒｐ５／６抗体及び使用方法
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
JP7418332B2 (ja) 2017-12-19 2024-01-19 スロゼン オペレーティング， インコーポレイテッド 抗フリズルド抗体及び使用方法
MX2021001507A (es) 2018-08-07 2021-04-28 Sumitomo Pharma Co Ltd Farmaco de diagnostico y metodo de diagnostico para la enfermedad de alzheimer.
KR20220137674A (ko) 2020-02-05 2022-10-12 스미토모 파마 가부시키가이샤 타우병증 및 인지증 관련 질환의 판정약 및 판정 방법
CN117157401A (zh) 2021-04-05 2023-12-01 公立大学法人大阪 针对胰腺癌干细胞的抗体
CN121293357A (zh) 2022-08-22 2026-01-09 雅博得乐医疗公司 Dll3结合分子及其用途

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432A (en) 1848-02-01 Improvement in machinery for knitting
US18A (en) 1836-08-31 Thomas blanchard
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
EP0266032A1 (de) 1986-08-29 1988-05-04 Beecham Group Plc Modifiziertes fibrinolytisches Enzym
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
JPS649774A (en) 1987-07-02 1989-01-13 Fujitsu Ltd Thermal transfer printing method
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE68923048T2 (de) 1988-08-23 1995-11-16 Dana Farber Cancer Inst Inc Alpha-Subeinheit des LFA-1-Leukocyt-Adhäsions-Rezeptors.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH02189420A (ja) 1989-01-17 1990-07-25 Omron Tateisi Electron Co ディジタルパネルメータ
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0479909B1 (de) 1989-06-29 1996-10-30 Medarex, Inc. Bispezifische reagenzien für die aids-therapie
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
GB9100816D0 (en) 1991-01-15 1991-02-27 Unilever Plc Cosmetic composition
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
ATE255131T1 (de) * 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
EP0605522B1 (de) 1991-09-23 1999-06-23 Medical Research Council Methoden zur Herstellung humanisierter Antikörper
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JP3507073B2 (ja) 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド 特異的結合対の成員の製造方法
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
US6107059A (en) * 1992-04-29 2000-08-22 Affymax Technologies N.V. Peptide library and screening method
EP0656064B1 (de) 1992-08-17 1997-03-05 Genentech, Inc. Bispezifische immunoadhesine
DE69303494T2 (de) 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
WO1995007301A1 (en) 1993-09-07 1995-03-16 Smithkline Beecham Corporation Recombinant il4 antibodies useful in treatment of il4 mediated disorders
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
DK0941344T3 (da) 1996-11-27 2004-09-27 Genentech Inc Humaniserede anti-CD11a-antistoffer
DE69832970T2 (de) 1997-04-07 2006-08-10 Genentech, Inc., South San Francisco Humanisierte antikörper und verfahren zu ihrer herstellung
IL132240A0 (en) 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
CA2334170A1 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6849425B1 (en) * 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CA2398466A1 (en) 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗ｈｅｒ２抗体改変体
EP1551453A4 (de) 2002-06-17 2007-04-25 Us Gov Health & Human Serv Spezifitätsgrafting eines mäuseantikörpers auf ein menschliches gerüst
EP1532162B1 (de) * 2002-06-28 2013-08-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Humanisierter anti-tag-72 cc49 zur diagnose und therapie humaner tumore
EP1600459A3 (de) * 2002-06-28 2005-12-07 Domantis Limited Ligand
JP4943161B2 (ja) 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド 新規抗ｉｌ１３モノクローナル抗体での癌の処置
AU2006283174A1 (en) 2005-08-24 2007-03-01 Cell-Matrix, Inc. Combination therapies for inhibiting integrin-extracellular matrix interactions

Also Published As

Publication number Publication date
ES2337473T3 (es) 2010-04-26
WO2005080432A2 (en) 2005-09-01
EP2168986A3 (de) 2010-07-28
EP1716181B1 (de) 2009-12-16
DK1716181T3 (da) 2010-03-01
EP1716181A2 (de) 2006-11-02
US8580928B2 (en) 2013-11-12
US20060122377A1 (en) 2006-06-08
EP2168986A2 (de) 2010-03-31
WO2005080432A3 (en) 2006-02-16
AU2005214382B2 (en) 2011-08-04
CA2555820A1 (en) 2005-09-01
CA2555820C (en) 2016-01-19
US20110237779A1 (en) 2011-09-29
EP3653641A1 (de) 2020-05-20
DE602005018325D1 (de) 2010-01-28
AU2005214382A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
DE602005018325D1 (de) Antikörper mit korrigierten cdr
ATE434626T1 (de) Humanisierter antikörper gegen cd4 mit immunsuppressiven merkmalen
TW200616662A (en) Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
TW200700081A (en) Anti-ctla-4 antibody compositions
WO2005069970A3 (en) Antibody specificity transfer using minimal essential binding determinants
NZ602294A (en) Monoclonal antibodies against c-met
CR20150102A (es) Anticuerpos que se unen a il-4 y/o il-13 (divisional 2)
CR20110577A (es) Proteínas de unión a il-1
CY1126083T1 (el) Μοντελα τρωκτικων και θεραπευτικα μορια
NZ592214A (en) Improved Interleukin-6 receptor antibody molecule
IL180152A0 (en) Chimeric and humanised monoclonal antibodies against inteleukin-13
IL191217A (en) Anti-17 mantle monoclonal antibody
DE60235588D1 (de) Monoklonales Antikörper gegen das HCV Kernantigen
NZ604090A (en) Human anti-b7rp1 neutralizing antibodies
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
NZ621938A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
WO2009112245A9 (en) Antibody against the csf-1 r
PA8650001A1 (es) Formulaciones de anticuerpo
WO2007008943A3 (en) Optimized anti-ep-cam antibodies
NZ611269A (en) Neutralizing anti-ccl20 antibodies
NO20054351D0 (no) Monoklonalt antistoff og hybridom som produserer dette
NZ594668A (en) Humanised antibodies with anti-tumour activity
MX2008002161A (es) Anticuerpos quimericos con regiones de primate del nuevo mundo.
WO2008052108A3 (en) Methods for use in human-adapting monoclonal antibodies
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties